Using irAOP for non-clinical safety evaluation of biotechnology-derived pharmaceuticals and ATMPs: a paradigm shift into a systematic and holistic framework
The chances and opportunities in modern biology inspired devising new therapeutics are mind blowing. The promises reach from successfully treating so-far incurable diseases like cancer and certain infections, to modulating and fine tuning the immune response to prolong the lifespan by inhibiting agi...
Saved in:
| Main Authors: | Armin Braun, Susann Dehmel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Immunotoxicology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/1547691X.2024.2390920 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analyzing IL-2-induced vascular leakage with an irAOP as tool
by: Patricia Gogesch, et al.
Published: (2024-12-01) -
An overview of immune safety avatar: mimicking the effects of immunomodulatory therapies on the immune system
by: Vanessa Neuhaus, et al.
Published: (2024-12-01) -
Revival of recombinant IL-2 therapy – approaches from the past until today
by: Luise A. Roser, et al.
Published: (2024-12-01) -
ARM’s Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead
by: Paolo Morgese, et al.
Published: (2025-04-01) -
Current challenges and future directions of ATMPs in regenerative medicine
by: Fatemeh Abbasi Kakroodi, et al.
Published: (2025-12-01)